Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2496 participants
OBSERVATIONAL
2006-03-31
2008-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
3 Screen Electronic Alert
NCT00550082
Aventus Thrombectomy System Pulmonary Embolism Clinical Study
NCT05907564
Treatment of Low-Risk Submassive Pulmonary Embolism With FlowTriever
NCT05273762
Prognostication in Acute Pulmonary Embolism
NCT02733198
US Pivotal Clinical Study of the Adient Absorbable Filter for the Prevention of Pulmonary Embolism
NCT05127915
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Venous thromboembolism (VTE) is often avoidable in hospitalized patients because proven prevention strategies have been established for patients at risk. North American and European prophylaxis guidelines have been widely disseminated. However, despite intensive educational efforts, VTE prevention remains underutilized.
At Brigham and Women's Hospital, we undertook a comprehensive program aimed at increasing the frequency of VTE prophylaxis in high risk patients. This novel strategy required: 1) devising a risk score that reliably and quickly identified patients at high risk of VTE, and 2) conducting a randomized controlled trial in which high risk patients without prophylaxis were randomized into an intervention or control group. The intervention group's physicians received a single alert explaining that the patient was at high risk, was not receiving prophylaxis, and urged that prophylaxis be selected from a template of available pharmacological and mechanical options. In contrast, the control group's physicians received no alert.
Each of 8 common risk factors was weighted according to a point scale. At least 4 score points were required to be deemed at "high risk" for VTE.
3 of the 8 risk factors were considered major and were assigned a score of 3 points each:
1. Cancer
2. Prior VTE
3. Hypercoagulability
One of the 8 risk factors, surgery, was considered intermediate and was assigned a score of 2.
4 of the 8 risk factors were considered minor and were assigned a score of 1 point each:
1. Advanced age (\> 70 years of age)
2. Obesity (Body Mass Index \> 29)
3. Bed rest
4. Hormone replacement therapy or oral contraceptives
There were 2,506 patients in the randomized controlled trial of a computer alert: 1255 in the intervention group and 1251 in the control group. The incidence of symptomatic VTE at 90 days was high: 8.2% in the control group. This high incidence validates the 8 risk factor and point score methodology.
The intervention group had an overall 41% reduction in VTE, without any increase in major bleeding. There was a 60% reduction in the incidence of symptomatic pulmonary embolism.
Identification of Patients at Risk for Venous Thromboembolism (VTE):
A VTE risk profile will be computed for each hospitalized patient using 8 common risk factors. Each risk factor is weighted according to a point score. To be included in this trial, the point score must equal or exceed 4 points.
Minor (Low) Risk Factors (1 POINT each):
* Advanced Age (\>70 years of age)
* Obesity (BMI \>29, or the presence of the word "obesity" in admission exam notes)
* Bed rest / Immobility (not related to surgery)
* Female Hormone Replacement Therapy or Oral Contraceptives
Intermediate Risk Factor (2 POINTS each):
· Major Surgery (\> 60 minutes)
Major (High) Risk Factors (3 POINTS each):
* Cancer (active)
* Prior VTE
* Hypercoagulability
Increased VTE risk is defined as a cumulative VTE risk score 4, so that patients with at least 1 major risk factor (cancer, prior VTE, or hypercoagulability) plus at least 1 additional intermediate risk factor (major surgery or bed rest) or minor risk factor (advanced age, obesity, or hormone replacement therapy/oral contraceptives) become eligible. In the absence of a major risk factor, patients with 1 intermediate risk factor plus at least 2 minor risk factors become eligible.
Screening for Venous Thromboembolism Prophylaxis:
If the cumulative VTE risk score is ³4, orders are reviewed to detect ongoing mechanical or pharmacological prophylactic measures. Mechanical prophylactic measures include graduated compression stockings and intermittent pneumatic compression devices. Pharmacological prophylactic measures include unfractionated heparin, enoxaparin, dalteparin, fondaparinux, tinzaparin, and warfarin.
Randomization:
Randomization Envelopes containing the statement "ALERT" (Intervention) or "NO ALERT" (Control) will be provided by Harvard Clinical Research Institute (HCRI), to randomize patients who meet all inclusion criteria.
The intervention is informing the responsible physician that: 1) his or her patient is at high risk for VTE, 2) is not receiving prophylaxis, and 3) VTE prophylaxis is recommended. For control patients, VTE prevention guidelines are available, but no specific prompt is provided to use them.
Follow Up:
Ninety-day follow-up is performed in all study patients by medical record review and through contact with the subject's Primary Care Physician.
Data Collection and Study Endpoints:
The primary endpoint is clinically diagnosed DVT or PE at 90 days. Safety endpoints include total mortality and hemorrhagic events at 30 and 90 days, respectively. We define major bleeding as intracranial, intraocular, retroperitoneal, pericardial, or bleeding that requires surgical intervention or that resulted in a hemoglobin loss greater than 3 g/l.
DVT is diagnosed if there is loss of vein compressibility by ultrasound or a filling defect by CT scan or by conventional contrast venography. PE is diagnosed by a positive contrast chest CT scan, a high-probability ventilation perfusion scan, or conventional pulmonary angiogram.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Alert
Physicians alerted about their high risk patients who are not receiving any VTE prophylaxis.
Human Alert
An alert from study staff informing a physician that his/her patient is at high risk for DVT and/or PE, but is not receiving any prophylaxis.
No Alert
Physicians not alerted about their high risk patients who are not receiving any VTE prophylaxis.
Human Alert
An alert from study staff informing a physician that his/her patient is at high risk for DVT and/or PE, but is not receiving any prophylaxis.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Human Alert
An alert from study staff informing a physician that his/her patient is at high risk for DVT and/or PE, but is not receiving any prophylaxis.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Cumulative VTE risk score \> 4
* Absence of pharmacologic or mechanical prophylaxis orders
* Patients from medical or surgical Services
Exclusion Criteria
* Current active pharmacologic or mechanical prophylaxis order
* Patients from the Department of Neurology, Newborn Service, Rehab Units, and Neonatal Intensive Care Unit (NICU).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
Brigham and Women's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Brigham and Women's Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Samuel Z. Goldhaber, MD
Role: PRINCIPAL_INVESTIGATOR
Brigham and Women's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AZ Pulmonary Specialists, Ltd
Scottsdale, Arizona, United States
Long Beach VA Hospital
Long Beach, California, United States
University of California - Irvine
Orange, California, United States
University of California - Davis
Sacramento, California, United States
University of Colorado Health Sciences Center
Denver, Colorado, United States
Norwalk Hospital
Norwalk, Connecticut, United States
William W. Backus Hospital
Norwich, Connecticut, United States
Washington Hospital Center
Washington D.C., District of Columbia, United States
Florida Hospital
Orlando, Florida, United States
Emory-Crawford Long Hospital
Atlanta, Georgia, United States
Franklin Square Hospital
Baltimore, Maryland, United States
Washington County Hospital
Hagerstown, Maryland, United States
Lahey Clinic
Burlington, Massachusetts, United States
North Shore Medical Center
Salem, Massachusetts, United States
Henry Ford Hospital K15
Detroit, Michigan, United States
St. Joseph Mercy Hospital
Ypsilanti, Michigan, United States
University of Missouri
Columbia, Missouri, United States
North Shore University Hospital
Great Neck, New York, United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Thomas Jefferson Hospital
Philadelphia, Pennsylvania, United States
Washington Hospital
Washington, Pennsylvania, United States
Spartanburg Regional Medical Center
Spartanburg, South Carolina, United States
Presbyterian Hospital of Dallas
Dallas, Texas, United States
LDS Hospital
Salt Lake City, Utah, United States
University of Utah Medical Center
Salt Lake City, Utah, United States
United Hospital System
Kenosha, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Goldhaber SZ, Turpie AG. Prevention of venous thromboembolism among hospitalized medical patients. Circulation. 2005 Jan 4;111(1):e1-3. doi: 10.1161/01.CIR.0000150393.51958.54. No abstract available.
Goldhaber SZ, Dunn K, MacDougall RC. New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment. Chest. 2000 Dec;118(6):1680-4. doi: 10.1378/chest.118.6.1680.
Goldhaber SZ, Tapson VF; DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 2004 Jan 15;93(2):259-62. doi: 10.1016/j.amjcard.2003.09.057.
Kucher N, Koo S, Quiroz R, Cooper JM, Paterno MD, Soukonnikov B, Goldhaber SZ. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005 Mar 10;352(10):969-77. doi: 10.1056/NEJMoa041533.
Piazza G, Rosenbaum EJ, Pendergast W, Jacobson JO, Pendleton RC, McLaren GD, Elliott CG, Stevens SM, Patton WF, Dabbagh O, Paterno MD, Catapane E, Li Z, Goldhaber SZ. Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients. Circulation. 2009 Apr 28;119(16):2196-201. doi: 10.1161/CIRCULATIONAHA.108.841197. Epub 2009 Apr 13.
Related Links
Access external resources that provide additional context or updates about the study.
North American Thrombosis Forum
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2005-P-002527
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.